Orchestra BioMed Holdings, Inc. (OBIO) received a second FDA Breakthrough Device Designation for its Atrioventricular Interval Modulation (AVIM) Therapy, extending the indication to patients with uncontrolled hypertension who also have pacemakers. The designation builds on the original pacemaker‑indicated cohort and broadens the U.S. addressable market to more than 7.7 million patients.
The FDA’s decision follows data from the company’s BACKBEAT pivotal trial, which is being conducted in partnership with Medtronic. The trial’s updated protocol expands eligibility, and the collaboration gives Medtronic the right of first negotiation for global commercialization rights. The designation signals confidence in the clinical data and accelerates the review and potential approval process for AVIM Therapy.
From a commercial perspective, the expanded patient population opens new reimbursement opportunities, including potential eligibility for New Technology Add‑on Payment (NTAP) and Transitional Pass‑Through (TPT) programs. The partnership with Medtronic also positions OBIO to integrate AVIM into future pacemaker platforms, potentially increasing market penetration and revenue streams.
OBIO’s Q4 2025 financial results provide context for the regulatory milestone. The company reported revenue of $30.92 million and earnings per share of $0.26, a beat of $0.69 against consensus expectations of –$0.38. Revenue also surpassed the consensus estimate of $0.93 million. The company’s cash balance was $106.5 million as of December 31 2025, supporting continued investment in the BACKBEAT trial and other development activities.
David Hochman, Chairman and CEO, said, “We are pleased to receive this additional Breakthrough Device Designation from the FDA. We believe it is directly aligned with the patient population being studied in our ongoing BACKBEAT Trial which we are executing in collaboration with Medtronic.” He added, “Continued alignment from the FDA, alongside our strategic relationship with Medtronic and accelerated enrollment in the BACKBEAT Trial, puts us in a strong position to advance AVIM Therapy to pivotal trial results.”
The second BDD reinforces OBIO’s strategic trajectory, enhancing its competitive positioning in the hypertension‑device intersection and laying the groundwork for future milestone payments and royalty revenue as the therapy moves toward commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.